Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
Masaaki Kondo(Yokohama City University Medical Center), Katsuaki Tanaka(Yokohama City University Medical Center), Masataka Taguri(Yokohama City University), Takeshi Hatanaka(Gunma Saiseikai Maebashi Hospital), Kazushi Numata(Yokohama City University Medical Center), Satoshi Kobayashi(Kanagawa Cancer Center), Hiroshi Aikata(Hiroshima Prefectural Hospital), Takahide Nakazawa(Kitasato University Hospital), Takako Ishibashi(Yokohama City University Hospital), Kotaro Matsunaga(St. Marianna University School of Medicine), Daichi Takizawa(Isesaki Fukushima Hospital), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Chiaki Okuse(St. Marianna University School of Medicine), Shinichi Ohkawa(National Cancer Center Hospital East), Shin Maeda(University of Tokyo Hospital), Michihiro Suzuki(Tamagawa University), Hisashi Hidaka(Kitasato University)
Cited by 77
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625